Pegylated recombinant human hyaluronidase - Halozyme

Drug Profile

Pegylated recombinant human hyaluronidase - Halozyme

Alternative Names: PEG PH20; PEG rHuPH-20; PEGylated reombinant human hyaluronidase - Halozyme; Pegylated rHuPH20

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Developer Eisai Co Ltd; Halozyme Therapeutics; University of California at San Francisco
  • Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
  • Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 05 Jan 2017 Updated efficacy data from the phase II Study 202 trial in Pancreatic cancer (Combination therapy, Metastatic disease) released by Halozyme
  • 10 Nov 2016 Halozyme Therapeutics and Genentech agree to co-develop pegylated recombinant human hyaluronidase in Cancer
  • 10 Nov 2016 Halozyme and Genentech plan a phase Ib/II clinical trial in Gastric and Pancreatic cancer (Combination therapy) in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top